ELECtric Tibial nerve stimulation to Reduce Incontinence in Care homes: protocol for the ELECTRIC randomised trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
16 Dec 2019
Historique:
received: 18 07 2019
accepted: 13 09 2019
entrez: 18 12 2019
pubmed: 18 12 2019
medline: 1 9 2020
Statut: epublish

Résumé

Urinary incontinence (UI) is highly prevalent in nursing and residential care homes (CHs) and profoundly impacts on residents' dignity and quality of life. CHs predominantly use absorbent pads to contain UI rather than actively treat the condition. Transcutaneous posterior tibial nerve stimulation (TPTNS) is a non-invasive, safe and low-cost intervention with demonstrated effectiveness for reducing UI in adults. However, the effectiveness of TPTNS to treat UI in older adults living in CHs is not known. The ELECTRIC trial aims to establish if a programme of TPTNS is a clinically effective treatment for UI in CH residents and investigate the associated costs and consequences. This is a pragmatic, multicentre, placebo-controlled, randomised parallel-group trial comparing the effectiveness of TPTNS (target n = 250) with sham stimulation (target n = 250) in reducing volume of UI in CH residents. CH residents (men and women) with self- or staff-reported UI of more than once per week are eligible to take part, including those with cognitive impairment. Outcomes will be measured at 6, 12 and 18 weeks post randomisation using the following measures: 24-h Pad Weight Tests, post void residual urine (bladder scans), Patient Perception of Bladder Condition, Minnesota Toileting Skills Questionnaire and Dementia Quality of Life. Economic evaluation based on a bespoke Resource Use Questionnaire will assess the costs of providing a programme of TPTNS. A concurrent process evaluation will investigate fidelity to the intervention and influencing factors, and qualitative interviews will explore the experiences of TPTNS from the perspective of CH residents, family members, CH staff and managers. TPTNS is a non-invasive intervention that has demonstrated effectiveness in reducing UI in adults. The ELECTRIC trial will involve CH staff delivering TPTNS to residents and establish whether TPTNS is more effective than sham stimulation for reducing the volume of UI in CH residents. Should TPTNS be shown to be an effective and acceptable treatment for UI in older adults in CHs, it will provide a safe, low-cost and dignified alternative to the current standard approach of containment and medication. ClinicalTrials.gov, NCT03248362. Registered on 14 August 2017. ISRCTN, ISRCTN98415244. Registered on 25 April 2018. https://www.isrctn.com/.

Sections du résumé

BACKGROUND BACKGROUND
Urinary incontinence (UI) is highly prevalent in nursing and residential care homes (CHs) and profoundly impacts on residents' dignity and quality of life. CHs predominantly use absorbent pads to contain UI rather than actively treat the condition. Transcutaneous posterior tibial nerve stimulation (TPTNS) is a non-invasive, safe and low-cost intervention with demonstrated effectiveness for reducing UI in adults. However, the effectiveness of TPTNS to treat UI in older adults living in CHs is not known. The ELECTRIC trial aims to establish if a programme of TPTNS is a clinically effective treatment for UI in CH residents and investigate the associated costs and consequences.
METHODS METHODS
This is a pragmatic, multicentre, placebo-controlled, randomised parallel-group trial comparing the effectiveness of TPTNS (target n = 250) with sham stimulation (target n = 250) in reducing volume of UI in CH residents. CH residents (men and women) with self- or staff-reported UI of more than once per week are eligible to take part, including those with cognitive impairment. Outcomes will be measured at 6, 12 and 18 weeks post randomisation using the following measures: 24-h Pad Weight Tests, post void residual urine (bladder scans), Patient Perception of Bladder Condition, Minnesota Toileting Skills Questionnaire and Dementia Quality of Life. Economic evaluation based on a bespoke Resource Use Questionnaire will assess the costs of providing a programme of TPTNS. A concurrent process evaluation will investigate fidelity to the intervention and influencing factors, and qualitative interviews will explore the experiences of TPTNS from the perspective of CH residents, family members, CH staff and managers.
DISCUSSION CONCLUSIONS
TPTNS is a non-invasive intervention that has demonstrated effectiveness in reducing UI in adults. The ELECTRIC trial will involve CH staff delivering TPTNS to residents and establish whether TPTNS is more effective than sham stimulation for reducing the volume of UI in CH residents. Should TPTNS be shown to be an effective and acceptable treatment for UI in older adults in CHs, it will provide a safe, low-cost and dignified alternative to the current standard approach of containment and medication.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov, NCT03248362. Registered on 14 August 2017. ISRCTN, ISRCTN98415244. Registered on 25 April 2018. https://www.isrctn.com/.

Identifiants

pubmed: 31843002
doi: 10.1186/s13063-019-3723-7
pii: 10.1186/s13063-019-3723-7
pmc: PMC6915984
doi:

Banques de données

ClinicalTrials.gov
['NCT03248362']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

723

Subventions

Organisme : Health Technology Assessment Programme
ID : HTA 15/130/73
Organisme : Department of Health
ID : HTA/15/130/73
Pays : United Kingdom
Organisme : Department of Health
ID : 11/1021/02
Pays : United Kingdom
Organisme : Department of Health
ID : 08/1809/231
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Department of Health
ID : HTA/13/75/01
Pays : United Kingdom
Organisme : Department of Health
ID : PB-PG-0906-11387
Pays : United Kingdom
Organisme : Department of Health
ID : 15/130/73
Pays : United Kingdom

Références

Neurourol Urodyn. 2018 Feb;37(2):528-541
pubmed: 28731583
Int Urogynecol J. 2010 Sep;21(9):1065-70
pubmed: 20458465
Obstet Gynecol. 2007 Apr;109(4):909-16
pubmed: 17400853
BMC Geriatr. 2017 Jan 13;17(1):17
pubmed: 28086759
Neurourol Urodyn. 2018 Jan;37(1):501-509
pubmed: 28471525
J Wound Ostomy Continence Nurs. 2015 Jan-Feb;42(1):94-9
pubmed: 25549314
Age Ageing. 2010 Sep;39(5):549-54
pubmed: 20631404
Neurourol Urodyn. 2011 Mar;30(3):306-11
pubmed: 21305588
Age Ageing. 2015 Sep;44(5):736-44
pubmed: 26112402
Arch Gerontol Geriatr. 2012 Jul-Aug;55(1):49-54
pubmed: 21601929
BMJ Open. 2019 May 14;9(5):e026171
pubmed: 31092652
J Gerontol Nurs. 2016 Jun 03;:1-5
pubmed: 27263538
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
Neurourol Urodyn. 2007;26(1):3-7
pubmed: 17080415
Age Ageing. 2005 May;34(3):242-8
pubmed: 15863409
J Urol. 2003 Jun;169(6):2210-5
pubmed: 12771752
J Wound Ostomy Continence Nurs. 2012 May-Jun;39(3):303-15; quiz 316-7
pubmed: 22572899
Aust J Physiother. 2009;55(2):89-95
pubmed: 19463079
J Adv Nurs. 2007 Jan;57(1):15-31
pubmed: 17184371
Health Technol Assess. 2020 Mar;24(16):1-172
pubmed: 32216870
Clin Interv Aging. 2012;7:45-50
pubmed: 22334767
J Am Geriatr Soc. 2008 May;56(5):847-53
pubmed: 18384584
Clin Obstet Gynecol. 2007 Sep;50(3):720-34
pubmed: 17762420
Health Technol Assess. 2005 Mar;9(10):1-93, iii-iv
pubmed: 15774233
Eur Urol. 2006 Jun;49(6):1079-86
pubmed: 16460875
Neurourol Urodyn. 2015 Jun;34(5):398-406
pubmed: 24700771
Neurourol Urodyn. 2015 Nov;34(8):747-51
pubmed: 25154378
Am J Obstet Gynecol. 2013 Feb;208(2):146.e1-7
pubmed: 23159696
Neurourol Urodyn. 2019 Feb;38(2):433-477
pubmed: 30681183
Adv Urol. 2011;2011:757454
pubmed: 21687571
J Am Geriatr Soc. 2006 Sep;54(9):1325-33
pubmed: 16970638
J Am Med Dir Assoc. 2013 Apr;14(4):270-4
pubmed: 23206722
J Am Geriatr Soc. 1988 Jan;36(1):34-9
pubmed: 3335728
Res Rep Urol. 2014 Oct 03;6:131-8
pubmed: 25328867
Int J Urol. 2016 Mar;23(3):253-8
pubmed: 26690557
Urology. 2014 Sep;84(3):509-14
pubmed: 25168524

Auteurs

J Booth (J)

School of Health and Life Sciences, Glasgow Caledonian University, Govan Mbeki Building, Glasgow, G4 0BA, UK. J.Booth@gcu.ac.uk.

L Aucott (L)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

S Cotton (S)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

C Goodman (C)

Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK.

S Hagen (S)

Nursing, Midwifery and Allied Health Professions Research Unit (NMAHP RU), Glasgow Caledonian University, Glasgow, UK.

D Harari (D)

Guy's and St Thomas' NHS Foundation Trust, London, UK.

M Lawrence (M)

School of Health and Life Sciences, Glasgow Caledonian University, Govan Mbeki Building, Glasgow, G4 0BA, UK.

A Lowndes (A)

Playlist for Life, Unit 1/14, Govanhill Workspace, Glasgow,, UK.

L Macaulay (L)

School of Health and Life Sciences, Glasgow Caledonian University, Govan Mbeki Building, Glasgow, G4 0BA, UK.

G MacLennan (G)

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

H Mason (H)

Yunus Centre for Social Business and Health, Glasgow Caledonian University, Glasgow, UK.

D McClurg (D)

Nursing, Midwifery and Allied Health Professions Research Unit (NMAHP RU), Glasgow Caledonian University, Glasgow, UK.

J Norrie (J)

Usher Institute, Edinburgh University, Edinburgh, UK.

C Norton (C)

King's College London, London, UK.

C O'Dolan (C)

School of Health and Life Sciences, Glasgow Caledonian University, Govan Mbeki Building, Glasgow, G4 0BA, UK.

D A Skelton (DA)

School of Health and Life Sciences, Glasgow Caledonian University, Govan Mbeki Building, Glasgow, G4 0BA, UK.

C Surr (C)

School of Health and Community Studies, Leeds Beckett University, Leeds, UK.

S Treweek (S)

Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH